Device Authority partnership expands route into enterprise IoT security

Tern plc

Device Authority has strengthened its enterprise market positioning through a strategic partnership with Xalient, bringing its KeyScaler platform into a managed cybersecurity model focused on identity-led protection for IoT and OT environments.

Enterprises are continuing to expand connected device estates across operational settings, where unmanaged assets, long device lifecycles and fragmented security processes can increase exposure to cyber risk. As these environments become more complex, demand is shifting towards automated tools that can manage device identity, access and compliance at scale.

The partnership gives Xalient the ability to integrate Device Authority’s KeyScaler technology into its IoT security offering. This is intended to help enterprise customers protect connected devices across complex environments by automating key parts of the device identity lifecycle. These include secure onboarding, credential provisioning, certificate rotation, decommissioning and policy-driven access control.

The collaboration also reflects the growing importance of Zero Trust-aligned security models. Rather than relying on static perimeter defences, enterprises need ways to verify and manage users, devices, workloads and machine identities continuously. KeyScaler is designed for IoT and OT environments, where traditional IT security tools may not be sufficient and where automation can help reduce the burden on internal teams.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

Search